Iovance (IOVA) Q2 Revenue Jumps 93%

Iovance Biotherapeutics (NASDAQ:IOVA), a biotechnology company specializing in cell therapies for solid tumors, reported GAAP earnings on August 7, 2025. The standout news was a 93% year-over-year GAAP revenue growth compared to Q2 2024, driven by its Amtagvi T cell therapy, but both GAAP revenue and earnings fell short of Wall Street expectations. Revenue (GAAP) reached $60.0 million compared to the $67.1 million consensus, while the loss per share of $0.33 (GAAP) was deeper than the projected $0.28 loss. Higher costs, particularly in manufacturing and research and development, contributed to a larger net loss. Despite the revenue miss on a GAAP basis, the company demonstrated ongoing uptake for its core product and maintained its full-year financial guidance, reflecting steady operational progress in a pivotal launch year. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Iovance Biotherapeutics develops cell-based immunotherapies, with a focus on tumor-infiltrating lymphocyte (TIL) products for people with advanced cancers. Its core therapy is Amtagvi, a T cell therapy for advanced melanoma that became the first of its kind to earn regulatory approval for solid tumors.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool